Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase II trial

Yunfei Chen; Yanmei Xu; Yueting Huang; Ting Sun; Yuefen Hu; Feng Xue; Xuanwei Peng; Yinghui Lai; Zeping Zhou; Hu Zhou; Rongfu Zhou; Wei Liu; Xiaofan Liu; Huan Dong; Rongfeng Fu; Mankai Ju; Xinyue Dai; Huiyuan Li; Xiaonan Liu; Yueshen Ma; Zhen Song; Jun Peng; Renchi Yang; Lei Zhang

doi:10.1002/ajh.27141

Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase II trial

Am J Hematol. 2024 Jan;99(1):E22-E25. doi: 10.1002/ajh.27141. Epub 2023 Oct 26.

Authors

Yunfei Chen^{1

2}, Yanmei Xu^{1

2}, Yueting Huang³, Ting Sun^{1

2}, Yuefen Hu⁴, Feng Xue^{1

2}, Xuanwei Peng⁵, Yinghui Lai⁵, Zeping Zhou⁶, Hu Zhou⁷, Rongfu Zhou⁸, Wei Liu^{1

2}, Xiaofan Liu^{1

2}, Huan Dong^{1

2}, Rongfeng Fu^{1

2}, Mankai Ju^{1

2}, Xinyue Dai^{1

2}, Huiyuan Li^{1

2}, Xiaonan Liu^{1

2}, Yueshen Ma^{1

2}, Zhen Song^{1

2}, Jun Peng⁴, Renchi Yang^{1

2}, Lei Zhang^{1

2}

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, China.
² Tianjin Institutes of Health Science, Tianjin, China.
³ Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.
⁴ Department of Hematology, Qilu Hospital, Shandong University, Jinan, China.
⁵ The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
⁶ The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
⁷ Henan Cancer Hospital, Zhengzhou, China.
⁸ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.

PMID: 37883528
DOI: 10.1002/ajh.27141

No abstract available

Publication types

Clinical Trial, Phase II
Multicenter Study
Letter

MeSH terms

Benzoates / adverse effects
Hepatitis B virus
Hepatitis B* / complications
Hepatitis B* / drug therapy
Humans
Hydrazines / adverse effects
Prospective Studies
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
Thrombocytopenia* / drug therapy
Treatment Outcome

Substances

eltrombopag
Benzoates
Hydrazines

Publication types

MeSH terms

Substances

Grants and funding